GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Open accessThe DOI matches its Crossref record; 143 of the 145 references it cites were found in a registry or an index; 12 of the 131 sources its claims cite were checked for support.
Abstract
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence that GLP-1 receptor agonists, including short-acting and long-acting agents, reduce body weight in obese and diabetic populations and are promising anti-obesity treatments. It also briefly covers dual/triple incretin agonists and calls for more long-term safety and efficacy data, especially in non-diabetic and non-Western populations.
Key findings
- In the STEP1 trial, 1,961 non-diabetic adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities received semaglutide 2.4 mg weekly for 68 weeks and lost an average of 15.3 kg; 86.4% vs 31.5% achieved ≥5% weight loss, 69.1% vs 12.0% achieved ≥10%, and 50.5% vs 4.9% achieved ≥15% versus placebo.
- In STEP2, adults with overweight/obesity and type 2 diabetes lost -6.9 kg (-7%) with semaglutide 1 mg and -9.7 kg (-9.6%) with semaglutide 2.4 mg weekly.
- Liraglutide 3 mg daily produced average weight loss of 8.40 ± 7.3 kg over 56 weeks in 3,731 patients without type 2 diabetes; in another trial, liraglutide 1.2–3 mg daily gave 4.8–7.2 kg average weight loss versus 4.1 kg with orlistat.
- Tirzepatide 5–15 mg per week reduced body weight by 5.4–11.7 kg in the SURPASS 1–5 trials in patients with type 2 diabetes.
Methods
- Design: narrative review of GLP-1 receptor agonists for obesity treatment, including short-acting agents (beinaglutide, exenatide), once-daily agents (lixisenatide, liraglutide), once-weekly agents (semaglutide, dulaglutide, exenatide long-acting release, polyethylene glycol loxenatide), and dual/triple agonists.
- Data: evidence from prior animal experiments and human clinical trials, including named programs such as STEP, AWARD, GetGoal, SCALE, and SURPASS; the review also includes a comparison table of anti-obesity drugs and schematic figures.
- Analysis: narrative synthesis of cited studies, with no systematic search strategy, meta-analysis, or risk-of-bias assessment described.
Limitations
- The paper states that the mechanism of GLP-1R in treating obesity is still uncertain and that more clinical evidence is needed for long-term safety and efficacy.
- The paper states that except for liraglutide and semaglutide, there are few related clinical studies of other GLP-1R agonists, especially in obese or overweight people without diabetes.
- The paper states that the race of patients in semaglutide-related clinical studies is relatively small and that more clinical trials in Asian and African obese populations are expected; evident from the text, the review is narrative rather than systematic and does not report formal quality assessment or publication-bias checks.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
8 Valid · 3 Not valid · 86 Not checked · 9 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases.”
- Also stated in: § Introduction · boosted
“A systematic review and meta-analysis proved that weight loss had been shown to prevent and mitigate obesity-related complications (9).”
§ GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach > Abstract
What the sources say
- Partly supportedcites [9] Ma, 2017, Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis, BMJ sourceExperimental — accuracy not yet measured
Our copy of Ma et al. (BMJ 2017) supports only part of the claim: the Abstract (Results) and Discussion report high quality evidence that weight loss interventions decreased all cause (premature) mortality (RR 0.82, 95% CI 0.71–0.95; 18% relative reduction, six fewer deaths per 1000) in adults with obesity (BMI ≥30, ≥1 year follow-up). But the same Discussion states 'We were unable to show effects on cardiovascular and cancer mortality, or participants developing cardiovascular events or new cancers,' and the Results (Meta-analyses) give non-significant estimates for cardiovascular mortality (RR 0.93, 0.67–1.31), cancer mortality (RR 0.58, 0.30–1.11), new cardiovascular events (RR 0.93, 0.83–1.04) and new cancers (RR 0.92, 0.63–1.36). So the sweeping assertion that weight loss 'significantly reduces the risk of obesity-related complications and chronic diseases' overstates this source, which shows a significant effect on premature mortality only, in adults who are obese; type 2 diabetes prevention is mentioned merely as an already proven benefit from other trials. (LLM, conf=0.78)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In GetGoal-S, a subanalysis of GetGoal-S and GetGoal-F1 studies, they found that LIXI could significantly reduce subjects’ body weight (− 1.76 ± 0.20 kg;-1.12 kg; -2.6/2.7 kg), respectively (72–74).”
§ GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach > Experimental evidence of GLP-1R agonists > Long−acting GLP−1 receptor agonists: once-daily
What the sources say
- Supportedcites [72] Rosenstock, 2014, Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-s), J Diabetes Complications source
The Results (section 3.2.3, Body weight) report a significantly greater weight reduction with lixisenatide than placebo at Week 24, including the −1.76 ± 0.20 kg value. This GetGoal-S paper supports the first result in the citing sentence’s three-study list; the other values are not attributed to this source. (LLM, conf=0.92)
- Supportedcites [73] Bolli, 2014, Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1), Diabetes Med source
The Body weight section (p. 5) reports significant weight reductions versus placebo in GetGoal-F1, with least-squares mean changes of −2.6 kg and −2.7 kg for its two lixisenatide regimens. This source supports the final pair of values in the citing sentence’s respective list; it does not report the GetGoal-S or subanalysis values attributed to the other citations. (LLM, conf=0.91)
- Partly supportedcites [74] Onishi, 2015, Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of G et G oal- s, J Diabetes Investig sourceExperimental — accuracy not yet measured
The Results > Efficacy passage reports a −1.12 kg bodyweight change with lixisenatide in the Japanese GetGoal-S subanalysis, matching the figure attributed to this source. But the difference from placebo was not significant (P = 0.7628), as the Discussion also states. Thus the reported weight change is supported, but the claim that this subanalysis found a significant reduction is not. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Studies in knock-out mice confirms the significant potential for novel triple-acting hybrid peptides as therapeutic options for obesity (128).”
§ GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach > Others: GIPR/GLP-1R dual agonists and GIPR/GLP-1R/GCGR triagonists
What the sources say
- Partly supportedcites [128] Gault, 2013, A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice, J Biol Chem sourceExperimental — accuracy not yet measured
The Abstract says knockout-mouse studies confirmed that the peptide acts through GIP, GLP-1, and glucagon receptors, and that the overall data suggest therapeutic promise for obesity. It does not say the knockout studies themselves confirmed that therapeutic potential; the cited sentence combines those two conclusions and strengthens the latter. (LLM, conf=0.84)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals.”
§ GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach > Abstract
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity.”
- Also stated in: § Introduction · boosted
“Many clinical trials have proven GLP-1R agonists’ effectiveness and safety in treating or preventing obesity (14).”
§ GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach > Abstract
What the sources say
- Not checked yetcites [14] Brown, 2021, SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications, Lancet source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
32 more claims
Create a free account to see all 106 claims and to verify the 119 references still open.
- It may state two separate claims as one. 63
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most well-known mechanism through which GLP-1RAs affect weight loss is through the endocrine pathway, but its role in the nervous system should not be overlooked.415–417”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [415]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [4]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“However, obesity is a global health challenge with few drug options (100).”
BackgroundObesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 4×
“In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called “ileal braking” eff…”
BackgroundInfluentialFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Research works printed but not linked: 2
- Leon, 2017, Lixisenatide (Adlyxin), Pharm Ther, 42, 676
- Knudsen, 1999, Derivatives of glucagon-like peptide-1 suitable for once daily administration, Diabetes, 48
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Tobaiqy, M., & Elkout, H. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01694-7 · Cited by 88
Regulation of CD8+ T cells by lipid metabolism in cancer progression
Tang, Y., Chen, Z., Zuo, Q., & Kang, Y. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01224-z · Cited by 135
Metadata
- Authors
- Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F.
- Affiliations
- First Hospital of Jilin University (CN)
- ORCID
- Yang, Wei
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-01
- Volume
- 14
- Pages
- 1085799-1085799
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9945324
- OpenAlex
- W4319808936
- Cited by
- 248
- References
- 145
- Citations by year
- 2026: 56 · 2025: 86 · 2024: 88 · 2023: 18
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, obesity treatment, incretins, anti-obesity drugs, weight loss, obesity complications, obesity pharmacotherapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Obesity, Weight Loss, Anti-Obesity Agents, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. https://app.cochat.ai/papers/10.3389/fendo.2023.1085799
- The paper
- Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1085799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.